A Phase 1/2 interventional study of ENTR-601-44 and ENTR-601-44 - matching placebo in Duchenne Muscular Dystrophy (DMD), sponsored by Entrada Therapeutics, Inc.. Recruiting at 14 sites in 4 countries. Open to male participants aged 4 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Entrada Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom — 16 open to participants now, 26 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United Kingdom.
Among the 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom, this one is the 56th largest by planned enrollment of the 73 interventional ones that give a count, is one of 6 that started in 2025, is one of 11 in phase 1/2, reaches primary completion later than 14 of the 25 other live ones, and was the 77th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →16 of the 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in United Kingdom, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
University of Oxford · Sites in United Kingdom
Ages 1–3 · Men only · Healthy volunteers
Solid Biosciences Inc. · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 7–11 · Men only
Entrada Therapeutics, Inc. · Sites in United Kingdom, Belgium, Italy and 2 more countries
Ages 4–20 · Men only
Italfarmaco · Sites in United Kingdom, Belgium, Italy and 1 more country
Ages 2–6 · Men only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 20 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 37 · Phase 3 31 · Phase 4 1
First in 2007; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is close to the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 74 across the 73 interventional studies, 85 across the 11 observational. Of the 56 that completed or were terminated, 32 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 85 have an industry lead sponsor. The 10 most frequent:
Entrada Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Entrada Therapeutics, Inc. has 3 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
5 of the studies in Muscular Dystrophy, Duchenne with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
| NCT06280209BioMarin PharmaceuticalA Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy | 2027-04-14 |
| NCT06138639Solid Biosciences Inc.A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | 2027-05-06 |
| NCT07423026University of OxfordA Remote Study Using Technology to Assess Outcomes in DMD | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 85 studies in Muscular Dystrophy, Duchenne with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study of the investigational medicine ENTR-601-44 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition.
The researchers want to: Test how safe ENTR-601-44 is, learn about any side effects, and look at the potential positive effects of ENTR-601-44, compared to placebo. Placebo looks like the investigational medicine but does not contain any active ingredient. In this summary ENTR-601-44 and placebo are both called study treatments.
The study has 2 parts:
Part A
Part B
Participants will:
Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.
Principal inclusion criteria
Principal exclusion criteria
Use of the following medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous infusion every 6 weeks
Drug: ENTR-601-44
intravenous infusion every 6 weeks
Drug: ENTR-601-44 - matching placebo
intravenous infusion
intravenous infusion
Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and Open Label (OL) Period)
Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.
Time frame: From baseline through End of Study (up to 62 weeks).
Plasma, muscle, and urine concentration of ENTR-601-44 and its final metabolite (Part A and Open Label (OL) Period)
Time frame: From Baseline through End of Study (up to 62 weeks).
Change from baseline to End of Part A in dystrophin by Western blot from muscle biopsy (Part A)
Time frame: Baseline, End of Part A (up to 25 weeks)
Change from baseline to End of Part A in dystrophin expression and localization from muscle biopsy (Part A)
Time frame: Baseline, End of Part A (up to 25 weeks)
Percent change from baseline to End of Part A in exon 44 skipping measured in muscle biopsy at End of Study (Part A)
Time frame: Baseline, End of Part A (up to 25 weeks)
Anti-drug antibody (ADA) and anti-dystrophin antibody in serum (Part A and OL Period)
Time frame: From baseline through End of Study (up to 62 weeks).
Change from baseline to End of OL Period in 10-Meter Walk/Run (10MWR) (Part A and OL Period)
Time frame: Baseline, End of Study (up to 62 weeks)
Change from baseline to End of OL Period in Timed Rise from Floor (Part A and OL Period)
Time frame: Baseline, End of Study (up to 62 weeks)
Change from baseline to End of OL Period in Timed 4-Stair Climb (4SC) (Part A and OL Period)
Time frame: Baseline, End of Study (up to 62 weeks).
Change from baseline to End of OL Period in 95th centile Stride Velocity (SV95C) (Part A and OL Period)
Time frame: Baseline, End of Study (up to 62 weeks)
Change from baseline to End of OL Period in North Star Ambulatory Assessment (NSAA) (Part A and OL Period)
Ordinal scale with 0 as the minimum score and 34 as the maximum score (higher score - better outcome).
Time frame: Baseline, End of Study (up to 62 weeks)
Change from baseline to End of OL Period in Performance of the Upper Limb v2.0 (PUL 2.0) (Part A and OL Period)
Ordinal scale with 0 as the minimum score and 42 as the maximum score (higher score - better outcome).
Time frame: Baseline, End of Study (up to 62 weeks)
Plan to share: No — The datasets generated during and/or analysed during the current study are not expected to be made available due to due to the data's high commercial sensitivity.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Mar 2029, 44 months after the start.
Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 44 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →
Entrada Therapeutics, Inc.